Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Mymd Pharmaceuticals Inc
(NQ:
MYMD
)
2.090
-0.290 (-12.18%)
Streaming Delayed Price
Updated: 3:59 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mymd Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
Next >
Super CBD To the Rescue? This Company Thinks So
November 11, 2021
Photo by Kindel Media from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
MyMD Pharmaceuticals President Chris Chapman, M.D. Named Medical Honoree of the Year by the Arthritis Foundation
October 26, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21
October 19, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
A First-of-its-Kind Drug Candidate Targeting the Root Causes of Aging Could Soon Dominate Estimated $600 Billion Aging Market
October 18, 2021
Image on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga....
Via
Benzinga
Cramer Likes Azek And SoFi, But Said Owning This Stock Could Be Dreadful
October 08, 2021
On CNBC's "Mad Money Light...
Via
Benzinga
Benzinga Announces The 8 'Rising Star' Companies Being Featured On Its Next 'All Access' Show
October 06, 2021
Benzinga is thrilled to announce the guest lineup for our next All Access show, set to air Thursday, October 7 at 9:00 am ET. Thursday's Guest Lineup The theme...
Via
Benzinga
MyMD Pharmaceuticals to Detail its Two Upcoming Phase 2 Trials at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on October 7
October 05, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBD
September 22, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan
September 13, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals to Present its Novel Therapeutic Platforms for Extending Healthy Lifespan at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15
September 09, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Use of Lead Candidate MYMD-1 for Treating Fibrosis and Asthma
August 24, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
85 Biggest Movers From Yesterday
August 11, 2021
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX...
Via
Benzinga
MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases
August 10, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 Vaccine
August 10, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharma Stock Is Trading Higher As COVID-19 Candidate Effective In Suppressing Cytokine Storm
August 05, 2021
MyMD Pharmaceuticals Inc (NASDAQ: MYMD) announces that a human cell research study of its lead compound MYMD-1 found the drug to effectively suppress the cytokine storm...
Via
Benzinga
Exposures
COVID-19
MyMD Pharmaceuticals’ Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study
August 05, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals’ Lead Compound MYMD-1 Shows Commonality in Comparative Study with FDA-Approved Anti-Inflammatory and Anti-Autoimmune Drugs Used for Arthritis, Colitis and Dermatitis
July 27, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals Announces New Data from Comparative Study on Lead Compound MYMD-1
July 07, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
June 16, 2021
Gainers Satsuma Pharmaceuticals (NASDAQ:STSA
Via
Benzinga
MyMD Pharmaceuticals Set to Join Russell Microcap® Index
June 07, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals Appoints David Rini, Professor at the Johns Hopkins School of Medicine, to Scientific Advisory Board
May 17, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals Schedules Business Update Conference Call
May 12, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
April 28, 2021
Gainers Galera Therapeutics (NASDAQ:GRTX) stock moved upwards by 23.75% to $8.18 during Wednesday's after-market session. Today's trading volume for this security ended up...
Via
Benzinga
Johns Hopkins Medicine Researchers to Present Data on MyMD Pharmaceuticals’ Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit
April 28, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
32 Stocks Moving In Friday's Mid-Day Session
April 23, 2021
Gainers Sypris Solutions, Inc. (NASDAQ: SYPR) shares climbed 24.7% to $3.50 after the company said its electronics unit has won a contract for deep space program. MicroVision,...
Via
Benzinga
50 Biggest Movers From Friday
April 26, 2021
Gainers Sypris Solutions, Inc. (NASDAQ: SYPR) shares surged 59.1% to close at $4.47 on Friday after the company said its electronics unit has won a contract for deep space...
Via
Benzinga
MyMD Pharmaceuticals Announces Issuance of Allowance from United States Patent and Trademark Office for Synthetic Cannabinoid Compounds
April 22, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
April 22, 2021
Gainers Renalytix AI (NASDAQ:RNLX) stock moved upwards by 20.93% to $30.5 during Thursday's pre-market session. The market value of their outstanding shares is at $1.0...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
12 Health Care Stocks Moving In Wednesday's Intraday Session
April 21, 2021
Gainers Alterity Therapeutics (NASDAQ:ATHE) shares rose 17.59% to $1.47 during Wednesday's regular session. As of 12:31 EST, this security is trading at a volume of 55...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
April 21, 2021
Gainers Alterity Therapeutics (NASDAQ:ATHE) stock rose 23.16% to $1.54 during Wednesday's pre-market session. The company's market cap stands at $53.4 million....
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.